DiscoverResearch To Practice | Oncology VideosMetastatic BRCA-Negative Triple-Negative Breast Cancer — An Interview with Prof Peter Schmid on Optimal Management
Metastatic BRCA-Negative Triple-Negative Breast Cancer — An Interview with Prof Peter Schmid on Optimal Management

Metastatic BRCA-Negative Triple-Negative Breast Cancer — An Interview with Prof Peter Schmid on Optimal Management

Update: 2025-09-23
Share

Description

Featuring an interview with Prof Peter Schmid, including the following topics:

  • Response to immunotherapy in breast cancer subtypes (0:00 )
  • Tolerability of TROP2 antibody-drug conjugates (ADCs) for metastatic breast cancer (mBC) (3:51 )
  • Approaches to therapy for patients with HR-negative HER2-low and HER2-ultralow mBC (13:03 )
  • ADC structure and treatment-related adverse events (19:02 )
  • Available data from the Phase III ASCENT-04 trial evaluating sacituzumab govitecan with pembrolizumab as first-line therapy for patients with PD-L1-positive advanced triple-negative breast cancer (23:06 )
  • Novel ADCs and bispecific antibodies under investigation for mBC (28:30 )
  • Comparing datopotamab deruxtecan and sacituzumab govitecan for HR-positive disease (33:01 )
  • Clinical investigator perspectives on the Phase III DESTINY-Breast09 trial evaluating first-line trastuzumab deruxtecan with or without pertuzumab versus THP (docetaxel/rastuzumab/pertuzumab) for HER2-positive mBC (35:06 )

CME information and select publications

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Metastatic BRCA-Negative Triple-Negative Breast Cancer — An Interview with Prof Peter Schmid on Optimal Management

Metastatic BRCA-Negative Triple-Negative Breast Cancer — An Interview with Prof Peter Schmid on Optimal Management

Dr. Neil Love